MANE

Veradermics Inc

97.93

Aug 28 • 3:59 PM ET -3.88 (-3.81%)

97.93

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NYSE

Peers: ORKA KRYS RYTM BMRN VKTX ALNY INCY AXSM MDGL NBIX

| Held by: VTI IWM VXF IWO VTWO JGRO SCHA XPH IHE IWN

Scroll to Statements

Index	RUT
Market Cap	4.09B
Enterprise Value	3.27B
Income	-
Sales	-
Book/sh	19.49
Cash/sh	19.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Feb 04, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.03
P/C	4.99
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	70.53
Current Ratio	70.53
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-2.63
EPS next Q	-0.61
EPS this Y	15.85%
EPS next Y	7.89%
EPS next 5Y	21.43%
EPS past 3/5Y	-117.94% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-44.05%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	11.40% -

Insider Own	27.61%
Insider Trans	-7.69%
Inst Own	69.80%
Inst Trans	22.17%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.40%
SMA50	-11.95%
SMA200	12.70%
Trades

Shs Outstand	41.78M
Shs Float	30.25M
Short Float	13.26%
Short Ratio	5.54
Short Interest	4.01M
52W High	131.24 -25.38%
52W Low	32.00 206.03%
Volatility	5.64% 5.98%
ATR (14)	6.63
RSI (14)	39.46
Beta	-
Rel Volume	0.86
Avg Volume	724.70K
Volume	623,726

Perf Week	-4.76%
Perf Month	-6.40%
Perf Quarter	-2.95%
Perf Half Y	113.59%
Perf YTD	188.03%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	163.50
Prev Close	101.81
Price	97.93
Change %	-3.81%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-26	Initiated	B. Riley Securities	Buy	$170
Jun-02-26	Initiated	Needham	Buy	$136
Mar-02-26	Initiated	Leerink Partners	Outperform	$75
Mar-02-26	Initiated	Jefferies	Buy	$75
Mar-02-26	Initiated	Citigroup	Buy	$85
Mar-02-26	Initiated	Cantor Fitzgerald	Overweight

Aug-11-26 06:11PM	Veradermics: Q2 Earnings Snapshot (Associated Press)
07:30AM	Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
Jul-17-26 07:30AM	Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study '302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy (Business Wire) +5.19%
Jul-15-26 09:35AM	Veradermics shares climb 9% after encouraging female hair loss trial results (MANE) (InvestorsHub) +12.28%
07:00AM	Veradermics Oral VDPHL01 Delivers Positive Study 207 Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study 306 Readout (Business Wire)
06:54PM	Loading…
Jul-14-26 06:54PM	Veradermics to Hold Conference Call to Discuss Study '207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss (Business Wire)
May-28-26 04:30PM	Veradermics to Present at Upcoming June Investor Conferences (Business Wire)
May-27-26 07:30AM	Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 302 Study of VDPHL01 at the 2026 World Congress for Hair Research (Business Wire)
May-15-26 04:52AM	The IPO Boom Isn't in Tech and AI-Yet (Barrons.com) -5.99%
May-14-26 01:09PM	Cerebras Swings IPO Focus to Tech and AI. But Healthcare and Industrials Still Lead. (Barrons.com)
07:30AM	Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium (Business Wire)
May-12-26 05:13PM	Veradermics: Q1 Earnings Snapshot (Associated Press)
07:30AM	Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
Apr-29-26 10:32PM	Veradermics Announces Pricing of Upsized Public Offering and Private Placement (Business Wire) -7.09%
Apr-27-26 05:26PM	Veradermics Announces Launch of Public Offering (Business Wire) +47.55%
09:52AM	Loading…
09:52AM	Veradermics Shares Jump 17% on Promising Hair Loss Trial Results (InvestorsHub)
09:31AM	How This Biotech, Up 25%, Is Taking A Page Out Of Rogaine's Playbook (Investor's Business Daily)
07:03AM	A new version of an old drug is helping men grow back some of their hair (MarketWatch)
07:00AM	Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss (Business Wire)
Apr-26-26 04:00PM	Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 302 Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss (Business Wire)
Apr-01-26 01:13PM	Squawk Pod: OpenAI's eye-popping raise & hair today, hair forever - 04/01/26 Audio Only (CNBC TV) -6.92%
Mar-30-26 07:30AM	Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates (Business Wire) -7.14%
Mar-18-26 07:00AM	Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting (Business Wire)
Mar-03-26 07:00AM	Veradermics to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-26-26 08:04PM	Flagship-Backed Generate Biomedicines Raises $400 Million in IPO (Bloomberg) +6.85%
07:39AM	For the first time in decades, new hair-loss treatments are in the works. Heres how theyre different. (MarketWatch)
Feb-25-26 03:36PM	For the first time in decades, new hair-loss treatments are in the works. Here's how they're different. (MarketWatch)
Feb-16-26 08:40AM	Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders (24/7 Wall St.)
Feb-12-26 08:55AM	NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell (PR Newswire)
Feb-09-26 07:30AM	Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss (Business Wire)
04:18PM	Loading…
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 04:05PM	Veradermics Announces Closing of Full Exercise of Underwriters Option to Purchase Additional Shares in Initial Public Offering (Business Wire)
Feb-04-26 04:12PM	No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. (Barrons.com)
01:07PM	This week's first IPO is set for a warm Wall Street welcome (MarketWatch)
08:55AM	NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA (PR Newswire)
Feb-03-26 09:57PM	Veradermics Announces Pricing of Upsized Initial Public Offering (Business Wire)

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

CEO & DirectorDr. Reid Waldman M.D.

CFO & TreasurerMr. Dominic Carrano C.P.A.

Chief Technical OfficerDr. Timothy Durso M.D.

General Counsel & SecretaryMr. Michael V. Greco J.D.

Senior Director of Manufacturing Sciences & TechnologyMr. Karl Pruss

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MONTANOVA CAPITAL, LLC	Director	Aug 19 '26	Sale	107.25	750,000	80,437,500	461,033	Aug 21 06:11 PM
Averill Master Fund, Ltd.	Affiliate	Aug 19 '26	Proposed Sale	107.25	690,601	74,066,957		Aug 19 07:14 PM
Averill Madison Master Fund, L	Affiliate	Aug 19 '26	Proposed Sale	107.25	59,399	6,370,543		Aug 19 07:12 PM
Durso Timothy August	Chief Technical Officer	Aug 17 '26	Option Exercise	12.19	3,452	42,080	121,642	Aug 18 09:10 PM
Durso Timothy August	Chief Technical Officer	Aug 17 '26	Sale	107.82	43,500	4,690,005	78,142	Aug 18 09:10 PM
Waldman Reid Alexander	Chief Executive Officer	Aug 17 '26	Option Exercise	12.19	3,452	42,080	238,324	Aug 18 09:04 PM
Waldman Reid Alexander	Chief Executive Officer	Aug 17 '26	Sale	107.86	67,500	7,280,713	170,824	Aug 18 09:04 PM
Timothy Durso	Officer	Aug 17 '26	Proposed Sale	111.28	87,000	9,681,360		Aug 17 05:39 PM
Reid Alexander Waldman	CEO	Aug 17 '26	Proposed Sale	111.28	135,000	15,022,800		Aug 17 05:30 PM
CHILDS JOHN W	Director	Aug 12 '26	Sale	107.12	100,000	10,711,700	194,117	Aug 14 06:01 PM
AMZL, LP	Shareholder	Aug 12 '26	Proposed Sale	108.95	104,587	11,394,754		Aug 12 06:01 PM
SR One Capital Fund II Aggrega	Shareholder	Aug 12 '26	Proposed Sale	108.95	217,162	23,659,800		Aug 12 06:00 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 04 '26	Buy	37.05	155,953	5,778,342	3,648,538	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 05 '26	Buy	37.99	96,200	3,655,079	489,932	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 06 '26	Buy	36.34	30,521	1,109,056	520,453	Feb 09 06:28 PM
Coric Vlad	Director	Feb 05 '26	Buy	17.00	117,646	1,999,982	319,398	Feb 05 07:04 PM
CHILDS JOHN W	Director	Feb 05 '26	Buy	17.00	294,117	4,999,989	2,202,006	Feb 05 07:04 PM
Longitude Capital Partners V,	10% Owner	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM
ENRIGHT PATRICK G	Director	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MANE

Veradermics Inc

Upgrade your Finviz experience